Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of PRAX-628 versus placebo in photosensitive epilepsy
NL-OMON59706Phase 2Completed
- Sponsor
- Praxis Precision Medicines
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of vormatrigine in epilepsy and photosensitive epilepsy (PSE) (2 arms), sponsored by Praxis Precision Medicines. Primary endpoint: Reduction or abolishment of the IPS-induced PPR. Started Jun 2023; status: completed.
02
Drugs
vormatrigine
03
Conditions
epilepsyphotosensitive epilepsy (PSE)
Beyond the preview
Go deeper on NL-OMON59706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59706.